LT3256579T - Cisteino proteazės - Google Patents
Cisteino proteazėsInfo
- Publication number
- LT3256579T LT3256579T LTEPPCT/EP2016/053054T LTEP2016053054T LT3256579T LT 3256579 T LT3256579 T LT 3256579T LT EP2016053054 T LTEP2016053054 T LT EP2016053054T LT 3256579 T LT3256579 T LT 3256579T
- Authority
- LT
- Lithuania
- Prior art keywords
- cysteine protease
- cysteine
- protease
- Prior art date
Links
- 102000005927 Cysteine Proteases Human genes 0.000 title 1
- 108010005843 Cysteine Proteases Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
- C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/2201—Streptopain (3.4.22.10)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201502305A GB201502305D0 (en) | 2015-02-12 | 2015-02-12 | Protein |
| PCT/EP2016/053054 WO2016128559A1 (en) | 2015-02-12 | 2016-02-12 | Cysteine protease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3256579T true LT3256579T (lt) | 2023-11-27 |
Family
ID=52781455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/EP2016/053054T LT3256579T (lt) | 2015-02-12 | 2016-02-12 | Cisteino proteazės |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US10758597B2 (enExample) |
| EP (2) | EP4265719A1 (enExample) |
| JP (1) | JP6879921B2 (enExample) |
| KR (1) | KR102524594B1 (enExample) |
| CN (2) | CN107532158A (enExample) |
| AU (1) | AU2016217801B2 (enExample) |
| BR (1) | BR112017017286A2 (enExample) |
| CA (1) | CA2976016C (enExample) |
| CL (1) | CL2017002066A1 (enExample) |
| CO (1) | CO2017009060A2 (enExample) |
| DK (1) | DK3256579T5 (enExample) |
| EA (1) | EA035896B1 (enExample) |
| ES (1) | ES2962794T3 (enExample) |
| FI (1) | FI3256579T3 (enExample) |
| GB (1) | GB201502305D0 (enExample) |
| HR (1) | HRP20231496T1 (enExample) |
| HU (1) | HUE064122T2 (enExample) |
| IL (1) | IL253939B (enExample) |
| LT (1) | LT3256579T (enExample) |
| MX (1) | MX391632B (enExample) |
| MY (1) | MY187486A (enExample) |
| PL (1) | PL3256579T3 (enExample) |
| PT (1) | PT3256579T (enExample) |
| RS (1) | RS64840B1 (enExample) |
| SG (1) | SG11201706349YA (enExample) |
| SI (1) | SI3256579T1 (enExample) |
| WO (1) | WO2016128559A1 (enExample) |
| ZA (1) | ZA201705114B (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201413240D0 (en) * | 2014-07-25 | 2014-09-10 | Hansa Medical Ab | Method |
| GB201502306D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| GB201502305D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| US20210228738A1 (en) | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
| CN108410798A (zh) * | 2018-03-27 | 2018-08-17 | 福建三造血技术有限公司 | 细胞分离用微珠洗脱液及配制方法 |
| JP2021519581A (ja) | 2018-04-03 | 2021-08-12 | ストライドバイオ，インコーポレイテッド | 抗体を回避するウイルスベクター |
| JP7425738B2 (ja) | 2018-04-03 | 2024-01-31 | ギンコ バイオワークス インコーポレイテッド | 眼組織を標的とするウイルスベクター |
| SG11202009452WA (en) | 2018-04-03 | 2020-10-29 | Stridebio Inc | Antibody-evading virus vectors |
| WO2020102740A2 (en) * | 2018-11-16 | 2020-05-22 | Spark Therapeutics, Inc. | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
| US20220143213A1 (en) * | 2019-01-28 | 2022-05-12 | Duke University | Composition and Methods for Evading Humoral Immunity |
| AU2020241888A1 (en) | 2019-03-21 | 2021-09-30 | Ginkgo Bioworks, Inc. | Recombinant adeno-associated virus vectors |
| DE102019112558A1 (de) | 2019-05-14 | 2020-11-19 | Claas Selbstfahrende Erntemaschinen Gmbh | Verfahren zur Wartung und/oder Reparatur einer landwirtschaftlichen Arbeitsmaschine |
| WO2021067598A1 (en) | 2019-10-04 | 2021-04-08 | Ultragenyx Pharmaceutical Inc. | Methods for improved therapeutic use of recombinant aav |
| KR20220083714A (ko) | 2019-10-17 | 2022-06-20 | 스트라이드바이오 인코포레이티드 | 니만-피크 질환 c형의 치료를 위한 아데노-연관 바이러스 벡터 |
| KR20230152810A (ko) * | 2019-12-06 | 2023-11-03 | 리제너론 파아마슈티컬스, 인크. | 항-vegf 단백질 조성물 및 이를 생산하는 방법 |
| PH12022551843A1 (en) * | 2020-01-22 | 2023-12-11 | Spark Therapeutics Inc | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
| GB202002072D0 (en) | 2020-02-14 | 2020-04-01 | Hansa Biopharma AB | immunoglobulin detection and associated therapies |
| BR112022015921A2 (pt) | 2020-02-14 | 2022-10-04 | Ultragenyx Pharmaceutical Inc | Terapia gênica para tratar o transtorno de deficiência de cdkl5 |
| GB202003129D0 (en) | 2020-03-04 | 2020-04-15 | Hansa Biopharma AB | Conditioning regimen for transplant of stem cells |
| JP2023525034A (ja) | 2020-05-08 | 2023-06-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法 |
| GB202007431D0 (en) * | 2020-05-19 | 2020-07-01 | Hansa Biopharma AB | Cysteine protease |
| GB202007434D0 (en) | 2020-05-19 | 2020-07-01 | Hansa Biopharma AB | Methods |
| WO2021244628A1 (zh) | 2020-06-05 | 2021-12-09 | 上海宝济药业有限公司 | 一种酶和病毒的药物组合及其应用 |
| JP2023532219A (ja) * | 2020-06-18 | 2023-07-27 | 上海宝済薬業有限公司 | 免疫グロブリン分解酵素ＩｄｅＥの突然変異体 |
| AR123288A1 (es) | 2020-08-19 | 2022-11-16 | Stridebio Inc | Vectores de virus adenoasociados para el tratamiento del síndrome de rett |
| EP4215208A4 (en) * | 2020-09-21 | 2024-11-20 | Shanghai Bao Pharmaceuticals Co., Ltd. | PHARMACEUTICAL COMBINATION AND USE THEREOF |
| IL301955A (en) | 2020-10-07 | 2023-06-01 | Asklepios Biopharmaceutical Inc | Therapeutic delivery of an adeno-related protein-related protein (FKRP) virus for the treatment of dystroglycanopathy disorders, including limb girdle 21 |
| CA3216491A1 (en) | 2021-04-16 | 2022-10-20 | Asklepios Biopharmaceutical, Inc. | Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response |
| EP4079848A1 (en) * | 2021-04-22 | 2022-10-26 | Genovis Ab | Immunoglobulin cleaving enzyme |
| FR3125965B1 (fr) * | 2021-08-05 | 2024-06-21 | Mc Saf | Conjugués anticorps-médicament |
| WO2023019168A1 (en) | 2021-08-11 | 2023-02-16 | Ultragenyx Pharmaceutical Inc. | Compositions and methods for treating a muscular dystrophy |
| AU2022385450A1 (en) | 2021-11-15 | 2024-06-13 | Hansa Biopharma AB | Methods for enhancing adoptive cell transfer immunotherapies |
| US20250145730A1 (en) | 2021-12-16 | 2025-05-08 | Shanghai Bao Pharmaceuticals Co., Ltd. | Anti-immunoglobulin degrading enzyme-digested fc variant |
| EP4275701A1 (en) | 2022-05-13 | 2023-11-15 | Hansa Biopharma AB | Conditioning regimen for cell transplant |
| EP4302770A1 (en) | 2022-07-08 | 2024-01-10 | Hansa Biopharma AB | Regimen for enzymatic desensitisation |
| WO2024057095A1 (en) | 2022-09-14 | 2024-03-21 | Genovis Ab | Mutant protease |
| EP4349365A1 (en) | 2022-10-07 | 2024-04-10 | Hansa Biopharma AB | Co-treatment for gene therapy |
| CN115873833B (zh) * | 2022-11-08 | 2024-08-16 | 上海泰昶生物技术有限公司 | 生产免疫球蛋白g降解酶的工程菌株和工艺 |
| CN115998690B (zh) * | 2022-11-10 | 2024-07-26 | 上海泰昶生物技术有限公司 | 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺 |
| US12091694B2 (en) | 2022-11-18 | 2024-09-17 | Seismic Therapeutic, Inc. | Fc fusion molecules and uses thereof |
| EP4646476A1 (en) | 2023-01-06 | 2025-11-12 | Seismic Therapeutic, Inc. | Protease variants and uses thereof |
| WO2024206953A2 (en) * | 2023-03-29 | 2024-10-03 | Taktos Therapeutics Inc. | Ides variant proteins and methods of using the same |
| CN120303399A (zh) * | 2023-11-13 | 2025-07-11 | 上海宝济药业股份有限公司 | 一种免疫球蛋白降解酶IdeE的突变体 |
| WO2025256978A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Variants of igm and igg cleaving enzymes |
| WO2025256977A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Novel igm and igg cleaving enzymes |
| CN118497176B (zh) * | 2024-07-16 | 2025-01-21 | 苏州康聚生物科技有限公司 | 一种免疫球蛋白降解酶 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| WO1997015592A1 (en) * | 1995-10-23 | 1997-05-01 | Incyte Pharmaceuticals, Inc. | Novel human cysteine protease |
| CA2421278A1 (en) * | 1998-03-11 | 1999-09-16 | Genentech, Inc. | Novel polypeptides and nucleic acids encoding the same |
| AU1686302A (en) | 2000-12-21 | 2002-07-01 | Shire Biochem Inc | Streptococcus pyogenes antigens and corresponding dna fragments |
| GB0130228D0 (en) | 2001-12-18 | 2002-02-06 | Hansa Medica Ab | Protein |
| PT1901773E (pt) * | 2005-06-09 | 2012-06-06 | Hansa Medical Ab | Utilização da proteinase ides (de s. pyogenes) para o tratamento de doenças e rejeição de enxertos |
| GB0511769D0 (en) * | 2005-06-09 | 2005-07-20 | Hansa Medical Ab | Treatment |
| GB0624874D0 (en) * | 2006-12-13 | 2007-01-24 | Hansa Medical Ab | Treatment |
| EP2190984B1 (en) | 2007-09-14 | 2013-09-04 | Genovis Ab | Methods and kits for purification and detection of glycosylated IgG |
| AU2008336295B2 (en) * | 2007-12-13 | 2013-07-11 | Intervacc Ab | Improved immunizing composition |
| ES2388017T3 (es) | 2007-12-21 | 2012-10-05 | Roche Glycart Ag | Ensayo de estabilidad de anticuerpos |
| EP2394173B1 (en) | 2009-02-09 | 2015-03-25 | Roche Glycart AG | Immunoglobulin glycosylation pattern analysis |
| ES2948841T3 (es) * | 2010-05-26 | 2023-09-20 | Intervacc Ab | Vacuna contra infecciones estreptocócicas basada en proteínas de fusión recombinantes |
| GB201115841D0 (en) * | 2011-09-13 | 2011-10-26 | Genovis Ab | Protein and method |
| GB201201314D0 (en) | 2012-01-26 | 2012-03-07 | Isis Innovation | Composition |
| GB201316744D0 (en) | 2013-09-20 | 2013-11-06 | Genovis Ab | Method |
| GB201413240D0 (en) | 2014-07-25 | 2014-09-10 | Hansa Medical Ab | Method |
| GB201502305D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| GB201502306D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| US20210228738A1 (en) * | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
-
2015
- 2015-02-12 GB GB201502305A patent/GB201502305D0/en not_active Ceased
-
2016
- 2016-02-12 EP EP23180077.2A patent/EP4265719A1/en active Pending
- 2016-02-12 SI SI201631755T patent/SI3256579T1/sl unknown
- 2016-02-12 RS RS20231088A patent/RS64840B1/sr unknown
- 2016-02-12 AU AU2016217801A patent/AU2016217801B2/en active Active
- 2016-02-12 MY MYPI2017001125A patent/MY187486A/en unknown
- 2016-02-12 BR BR112017017286-0A patent/BR112017017286A2/pt not_active Application Discontinuation
- 2016-02-12 HR HRP20231496TT patent/HRP20231496T1/hr unknown
- 2016-02-12 EP EP16704223.3A patent/EP3256579B1/en active Active
- 2016-02-12 MX MX2017010389A patent/MX391632B/es unknown
- 2016-02-12 CN CN201680021602.2A patent/CN107532158A/zh active Pending
- 2016-02-12 ES ES16704223T patent/ES2962794T3/es active Active
- 2016-02-12 DK DK16704223.3T patent/DK3256579T5/da active
- 2016-02-12 CN CN202110810280.2A patent/CN113564150B/zh active Active
- 2016-02-12 US US15/550,318 patent/US10758597B2/en active Active
- 2016-02-12 CA CA2976016A patent/CA2976016C/en active Active
- 2016-02-12 KR KR1020177025524A patent/KR102524594B1/ko active Active
- 2016-02-12 WO PCT/EP2016/053054 patent/WO2016128559A1/en not_active Ceased
- 2016-02-12 PL PL16704223.3T patent/PL3256579T3/pl unknown
- 2016-02-12 JP JP2017542900A patent/JP6879921B2/ja active Active
- 2016-02-12 SG SG11201706349YA patent/SG11201706349YA/en unknown
- 2016-02-12 FI FIEP16704223.3T patent/FI3256579T3/fi active
- 2016-02-12 EA EA201791775A patent/EA035896B1/ru not_active IP Right Cessation
- 2016-02-12 HU HUE16704223A patent/HUE064122T2/hu unknown
- 2016-02-12 PT PT167042233T patent/PT3256579T/pt unknown
- 2016-02-12 LT LTEPPCT/EP2016/053054T patent/LT3256579T/lt unknown
-
2017
- 2017-07-27 ZA ZA2017/05114A patent/ZA201705114B/en unknown
- 2017-08-10 IL IL253939A patent/IL253939B/en active IP Right Grant
- 2017-08-11 CL CL2017002066A patent/CL2017002066A1/es unknown
- 2017-09-04 CO CONC2017/0009060A patent/CO2017009060A2/es unknown
-
2020
- 2020-02-17 US US16/792,747 patent/US11524057B2/en active Active
-
2022
- 2022-11-08 US US18/053,676 patent/US20230302100A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL253939A0 (en) | cysteine protease | |
| IL253938A0 (en) | cysteine protease | |
| DK3320033T3 (en) | Polyethylenterephthalat-depolymerisering | |
| AU364424S (en) | Watchcase | |
| AU364423S (en) | Watchcase | |
| DK3373882T3 (en) | Patientisolator | |
| IL253635A0 (en) | Cyclopropanebenzofuranyl pyridopyrazinedione type compounds | |
| PL3458583T3 (pl) | Proteazy o polepszonej skuteczności | |
| GB201506316D0 (en) | Novel peptide | |
| GB201417288D0 (en) | Cysteine labelling | |
| GB201513444D0 (en) | Peptoid | |
| EP3104705A4 (en) | Cathepsin cysteine protease inhibitors | |
| GB201502316D0 (en) | Bitcon technology | |
| GB201502073D0 (en) | HDEG technology | |
| HUP1500342A2 (en) | Cylinder-head | |
| GB201506360D0 (en) | Novel peptide | |
| AU366552S (en) | Nutblock | |
| GB201516577D0 (en) | Project P | |
| GB201415235D0 (en) | Trans-locating peptide | |
| GB201509154D0 (en) | Lookma | |
| GB201505170D0 (en) | Concept 36A | |
| GB201508477D0 (en) | Globaldrum | |
| GB201404910D0 (en) | Trans-locating peptide | |
| GB201508451D0 (en) | Tri-plane | |
| GB201507980D0 (en) | Bio-cite |